Last reviewed · How we verify
Afluria® Quadrivalent
Afluria Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
Afluria Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Afluria® Quadrivalent |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing four circulating strains (two influenza A subtypes and two influenza B lineages). Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that provide protection against infection with matching influenza strains.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness
- Injection site erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |